NCT01089517View on ClinicalTrials.gov

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

PHASE2CompletedINTERVENTIONAL
Enrollment

449

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

E10030 plus Lucentis

once a month intravitreal injection

DRUG

Lucentis

10 mg/mL intravitreal injection monthly

Trial Locations (1)

29169

Palmetto Retinal Center, West Columbia

Sponsors
All Listed Sponsors
lead

Ophthotech Corporation

INDUSTRY